Kai-Fu Lee

Kai-Fu Lee is a world-renowned advisor, speaker, and investor in the technology industry. Kai-Fu is currently an advisor at Insilico Medicine, a leading company in artificial intelligence for drug discovery, digital biomarkers, and aging research.

Prior to joining Insilico Medicine, Kai-Fu served as the Senior Group Lead of Medicinal Chemistry at Jiangsu Hansoh Pharmaceutical Group Co., Ltd. from January 2020 to January 2021. In this role, they were responsible for the medicinal chemistry division and led a team of scientists to develop new drugs and therapies.

From November 2016 to January 2020, Kai-Fu worked as a Senior Scientist & Project Leader at The Janssen Pharmaceutical Companies of Johnson & Johnson. Kai-Fu was a core team player of an oncology project (PPI target) in LO stage and made major contributions to optimizing PK profiles and mitigating specific toxicity issues. Kai-Fu was also the chemistry leader of a back-up covalent inhibition strategy of this project, established the whole set of essential specific assays by efficient cross-function collaboration, led the SAR evolution and enabled the POC of PK-PD relationship model. In addition, Kai-Fu was the chemistry leader of an exploratory oncology project (epigenetic target) and a core team player of an oncology project (kinase target) in LO and LLO stage. Kai-Fu made significant impacts on optimizing physicochemical properties and safety margin.

During their time at Johnson & Johnson, Kai-Fu was also a people manager, supervising in-line reports with excellent performance. Kai-Fu also managed CRO FTEs (contract research organization).

Kai-Fu has received numerous awards and accolades throughout their career. In 2017, they received the Janssen Encore Award - GOLD AWARD. This award is given to Janssen employees who have made significant contributions to the success of the company.

Kai-Fu Lee received a Ph.D. in Chemistry from Boston College and a B.S. in Chemistry from Fudan University.